Medical genetics and epigenetics of telomerase

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 3, 2011, Pages 457-467

  Koziel, Jillian E ^a   Fox, Melanie J ^a   Steding, Catherine E ^a   Sprouse, Alyssa A ^a   Herbert, Brittney Shea ^a,b,c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY   (United States)

Author keywords

Epigenetics; Gene variation; Medical genetics; MiRNAs; SNPs; Telomerase; TERRA

Indexed keywords

MICRORNA; SIRT1 PROTEIN, HUMAN; SIRTUIN 1; TELOMERASE;

DNA METHYLATION; EPIGENETICS; GENETIC PREDISPOSITION; GENETICS; HUMAN; MEDICAL GENETICS; METABOLISM; MUTATION; REVIEW;

DNA METHYLATION; EPIGENOMICS; GENETIC PREDISPOSITION TO DISEASE; GENETICS, MEDICAL; HUMANS; MICRORNAS; MUTATION; SIRTUIN 1; TELOMERASE;

EID: 79953311697     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01276.x     Document Type: Review

References (108)

1. Blackburn EH. Structure and function of telomeres. Nature. 1991; 350: 569-73.
2. Moyzis RK, Buckingham JM, Cram LS, et al A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc Natl Acad Sci USA. 1988; 85: 6622-6.
3. Makarov VL, Hirose Y, Langmore JP. Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening. Cell. 1997; 88: 657-66.
4. Griffith JD, Comeau L, Rosenfield S, et al Mammalian telomeres end in a large duplex loop. Cell. 1999; 97: 503-14.
5. Wei C, Price M. Protecting the terminus: t-loops and telomere end-binding proteins. Cell Mol Life Sci. 2003; 60: 2283-94.
6. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 2005; 19: 2100-10.
7. Osterhage JL, Friedman KL. Chromosome end maintenance by telomerase. J Biol Chem. 2009; 284: 16061-5.
8. Blackburn EH. Telomeres and telomerase: their mechanisms of action and the effects of altering their functions. FEBS Lett. 2005; 579: 859-62.
9. Morin GB. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell. 1989; 59: 521-9.
10. Feng J, Funk WD, Wang SS, et al The RNA component of human telomerase. Science. 1995; 269: 1236-41.
11. Shay JW, Wright WE. Telomerase therapeutics for cancer: challenges and new directions. Nat Rev Drug Discov. 2006; 5: 577-84.
12. Hills M, Lansdorp PM. Short telomeres resulting from heritable mutations in the telomerase reverse transcriptase gene predispose for a variety of malignancies. Ann NY Acad Sci. 2009; 1176: 178-90.
13. Cairney CJ, Keith WN. Telomerase redefined: integrated regulation of hTR and hTERT for telomere maintenance and telomerase activity. Biochimie. 2008; 90: 13-23.
14. Ly H. Genetic and environmental factors influencing human diseases with telomere dysfunction. Int J Clin Exp Med. 2009; 2: 114-30.
15. Deville L, Hillion J, Segal-Bendirdjian E. Telomerase regulation in hematological cancers: a matter of stemness Biochim Biophys Acta. 2009; 1792: 229-39.
16. Cong YS, Wright WE, Shay JW. Human telomerase and its regulation. Microbiol Mol Biol Rev. 2002; 66: 407-25, table of contents.
17. Liu L, Lai S, Andrews LG, et al Genetic and epigenetic modulation of telomerase activity in development and disease. Gene. 2004; 340: 1-10.
18. de Wilde J, Kooter JM, Overmeer RM, et al hTERT promoter activity and CpG methylation in HPV-induced carcinogenesis. BMC Cancer. 2010; 10: 271.
19. Kyo S, Takakura M, Fujiwara T, et al Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci. 2008; 99: 1528-38.
20. Iliopoulos D, Satra M, Drakaki A, et al Epigenetic regulation of hTERT promoter in hepatocellular carcinomas. Int J Oncol. 2009; 34: 391-9.
21. Gigek CO, Leal MF, Silva PN, et al hTERT methylation and expression in gastric cancer. Biomarkers. 2009; 14: 630-6.
22. Zinn RL, Pruitt K, Eguchi S, et al hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site. Cancer Res. 2007; 67: 194-201.
23. Azouz A, Wu YL, Hillion J, et al Epigenetic plasticity of hTERT gene promoter determines retinoid capacity to repress telomerase in maturation-resistant acute promyelocytic leukemia cells. Leukemia. 2010; 24: 613-22.
24. Schoeftner S, Blasco MA. Chromatin regulation and non-coding RNAs at mammalian telomeres. Semin Cell Dev Biol. 2010; 21: 186-93.
25. Palm W, de Lange T. How shelterin protects mammalian telomeres. Annu Rev Genet. 2008; 42: 301-34.
26. Martinez P, Blasco MA. Role of shelterin in cancer and aging. Aging Cell. 2010; 9: 653-66.
27. Ng LJ, Cropley JE, Pickett HA, et al Telomerase activity is associated with an increase in DNA methylation at the proximal subtelomere and a reduction in telomeric transcription. Nucleic Acids Res. 2009; 37: 1152-9.
28. Nittis T, Guittat L, Stewart SA. Alternative lengthening of telomeres (ALT) and chromatin: is there a connection Biochimie. 2008; 90: 5-12.
29. Haigis MC, Sinclair DA. Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol. 2010; 5: 253-95.
30. Lin SY, Elledge SJ. Multiple tumor suppressor pathways negatively regulate telomerase. Cell. 2003; 113: 881-9.
31. Narala SR, Allsopp RC, Wells TB, et al SIRT1 acts as a nutrient-sensitive growth suppressor and its loss is associated with increased AMPK and telomerase activity. Mol Biol Cell. 2008; 19: 1210-9.
32. Vorovich E, Ratovitski EA. Dual regulation of TERT activity through transcription and splicing by DeltaNP63alpha. Aging. 2009; 1: 58-67.
33. Baur JA. Biochemical effects of SIRT1 activators. Biochim Biophys Acta. 2010; 1804: 1626-34.
34. Baur JA, Pearson KJ, Price NL, et al Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006; 444: 337-42.
35. Pearce VP, Sherrell J, Lou Z, et al Immortalization of epithelial progenitor cells mediated by resveratrol. Oncogene. 2008; 27: 2365-74.
36. Lanzilli G, Fuggetta MP, Tricarico M, et al Resveratrol down-regulates the growth and telomerase activity of breast cancer cells in vitro. Int J Oncol. 2006; 28: 641-8.
37. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6: 857-66.
38. Lee CH, Subramanian S, Beck AH, et al MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary. PLoS One. 2009; 4: 1-11.
39. Nam EJ, Yoon H, Kim SW, et al MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res. 2008; 14: 2690-5.
40. Koturbash I, Zemp FJ, Pogribny I, et al Small molecules with big effects: the role of the microRNAome in cancer and carcinogenesis. Mutat Res. 2010. DOI: .
41. Mitomo S, Maesawa C, Ogasawara S, et al Downregulation of miR-138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines. Cancer Sci. 2008; 99: 280-6.
42. Wu YL, Dudognon C, Nguyen E, et al Immunodetection of human telomerase reverse-transcriptase (hTERT) re-appraised: nucleolin and telomerase cross paths. J Cell Sci. 2006; 119: 2797-806.
43. Miura N, Sato R, Tsukamoto T, et al A noncoding RNA gene on chromosome 10p15.3 may function upstream of hTERT. BMC Mol Biol. 2009; 10: 1-16.
44. Sasaki M, Honda T, Yamada H, et al Evidence for multiple pathways to cellular senescence. Cancer Res. 1994; 54: 6090-3.
45. Stark M, Hayward N. Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res. 2007; 67: 2632-42.
46. Steck PA, Ligon AH, Cheong P, et al Two tumor suppressive loci on chromosome 10 involved in human glioblastomas. Genes Chromosomes Cancer. 1995; 12: 255-61.
47. Azzalin CM, Reichenbach P, Khoriauli L, et al Telomeric repeat containing RNA and RNA surveillance factors at mammalian chromosome ends. Science. 2007; 318: 798-801.
48. Schoeftner S, Blasco MA. Developmentally regulated transcription of mammalian telomeres by DNA-dependent RNA polymerase II. Nat Cell Biol. 2008; 10: 228-36.
49. Azzalin CM, Lingner J. Telomeres: the silence is broken. Cell Cycle. 2008; 7: 1161-5.
50. Caslini C. Transcriptional regulation of telomeric non-coding RNA: implications on telomere biology, replicative senescence and cancer. RNA Biol. 2010; 7: 18-22.
51. Luke B, Lingner J. TERRA: telomeric repeat-containing RNA. EMBO J. 2009; 28: 2503-10.
52. Caslini C, Connelly JA, Serna A, et al MLL associates with telomeres and regulates telomeric repeat-containing RNA transcription. Mol Cell Biol. 2009; 29: 4519-26.
53. Carroll KA, Ly H. Telomere dysfunction in human diseases: the long and short of it Int J Clin Exp Pathol. 2009; 2: 528-43.
54. Knight SW, Heiss NS, Vulliamy TJ, et al X-linked dyskeratosis congenita is predominantly caused by missense mutations in the DKC1 gene. Am J Hum Genet. 1999; 65: 50-8.
55. Vulliamy TJ, Marrone A, Knight SW, et al Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. Blood. 2006; 107: 2680-5.
56. Dokal I. Dyskeratosis congenita in all its forms. Br J Haematol. 2000; 110: 768-79.
57. Rostamiani K, Klauck SM, Heiss N, et al Novel mutations of the DKC1 gene in individuals affected with dyskeratosis congenita. Blood Cells Mol Dis. 2010; 44: 88.
58. Du HY, Pumbo E, Manley P, et al Complex inheritance pattern of dyskeratosis congenita in two families with 2 different mutations in the telomerase reverse transcriptase gene. Blood. 2008; 111: 1128-30.
59. Xin ZT, Beauchamp AD, Calado RT, et al Functional characterization of natural telomerase mutations found in patients with hematologic disorders. Blood. 2007; 109: 524-32.
60. Marrone A, Stevens D, Vulliamy T, et al Heterozygous telomerase RNA mutations found in dyskeratosis congenita and aplastic anemia reduce telomerase activity via haploinsufficiency. Blood. 2004; 104: 3936-42.
61. Ly H, Schertzer M, Jastaniah W, et al Identification and functional characterization of 2 variant alleles of the telomerase RNA template gene (TERC) in a patient with dyskeratosis congenita. Blood. 2005; 106: 1246-52.
62. Vulliamy T, Marrone A, Szydlo R, et al Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat Genet. 2004; 36: 447-9.
63. Fogarty PF, Yamaguchi H, Wiestner A, et al Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA. Lancet. 2003; 362: 1628-30.
64. Vulliamy T, Marrone A, Goldman F, et al The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature. 2001; 413: 432-5.
65. Aspesi A, Vallero S, Rocci A, et al Compound heterozygosity for two new TERT mutations in a patient with aplastic anemia. Pediatr Blood Cancer. 2010; 55: 550-3.
66. Yamaguchi H, Calado RT, Ly H, et al Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med. 2005; 352: 1413-24.
67. Liang J, Yagasaki H, Kamachi Y, et al Mutations in telomerase catalytic protein in Japanese children with aplastic anemia. Haematologica. 2006; 91: 656-8.
68. Vulliamy T, Marrone A, Dokal I, et al Association between aplastic anaemia and mutations in telomerase RNA. Lancet. 2002; 359: 2168-70.
69. Ly H, Calado RT, Allard P, et al Functional characterization of telomerase RNA variants found in patients with hematologic disorders. Blood. 2005; 105: 2332-9.
70. Yamaguchi H, Baerlocher GM, Lansdorp PM, et al Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. Blood. 2003; 102: 916-8.
71. Tsakiri KD, Cronkhite JT, Kuan PJ, et al Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci USA. 2007; 104: 7552-7.
72. Armanios MY, Chen JJ, Cogan JD, et al Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med. 2007; 356: 1317-26.
73. Mushiroda T, Wattanapokayakit S, Takahashi A, et al A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis. J Med Genet. 2008; 45: 654-6.
74. Sealey DC, Zheng L, Taboski MA, et al The N-terminus of hTERT contains a DNA-binding domain and is required for telomerase activity and cellular immortalization. Nucleic Acids Res. 2010; 38: 2019-35.
75. Wyatt HD, Lobb DA, Beattie TL. Characterization of physical and functional anchor site interactions in human telomerase. Mol Cell Biol. 2007; 27: 3226-40.
76. Ashbridge B, Orte A, Yeoman JA, et al Single-molecule analysis of the human telomerase RNA.dyskerin interaction and the effect of dyskeratosis congenita mutations. Biochemistry. 2009; 48: 10858-65.
77. Robart AR, Collins K. Investigation of human telomerase holoenzyme assembly, activity, and processivity using disease-linked subunit variants. J Biol Chem. 2010; 285: 4375-86.
78. Vulliamy TJ, Dokal I. Dyskeratosis congenita: the diverse clinical presentation of mutations in the telomerase complex. Biochimie. 2008; 90: 122-30.
79. Dokal I, Vulliamy T. Inherited aplastic anaemias/bone marrow failure syndromes. Blood Rev. 2008; 22: 141-53.
80. Baird DM. Variation at the TERT locus and predisposition for cancer. Expert Rev Mol Med. 2010; 12: 1-21.
81. Aubert G, Lansdorp PM. Telomeres and aging. Physiol Rev. 2008; 88: 557-79.
82. Lansdorp PM. Telomeres and disease. EMBO J. 2009; 28: 2532-40.
83. Gu B, Bessler M, Mason PJ. Dyskerin, telomerase and the DNA damage response. Cell Cycle. 2009; 8: 6-10.
84. Knight SW, Vulliamy TJ, Morgan B, et al Identification of novel DKC1 mutations in patients with dyskeratosis congenita: implications for pathophysiology and diagnosis. Hum Genet. 2001; 108: 299-303.
85. Armanios M. Syndromes of telomere shortening. Annu Rev Genomics Hum Genet. 2009; 10: 45-61.
86. Alder JK, Chen JJ, Lancaster L, et al Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci USA. 2008; 105: 13051-6.
87. Calado RT, Regal JA, Hills M, et al Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. Proc Natl Acad Sci USA. 2009; 106: 1187-92.
88. Schlenk RF, Dohner K, Krauter J, et al Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008; 358: 1909-18.
89. Kirwan M, Vulliamy T, Marrone A, et al Defining the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemia. Hum Mutat. 2009; 30: 1567-73.
90. Savage SA, Chanock SJ, Lissowska J, et al Genetic variation in five genes important in telomere biology and risk for breast cancer. Br J Cancer. 2007; 97: 832-6.
91. Takeuchi J, Ly H, Yamaguchi H, et al Identification and functional characterization of novel telomerase variant alleles in Japanese patients with bone-marrow failure syndromes. Blood Cells Mol Dis. 2008; 40: 185-91.
92. Zhao Y, Wang S, Popova EY, et al Rearrangement of upstream sequences of the hTERT gene during cellular immortalization. Genes, Chromosomes Cancer. 2009; 48: 963-74.
93. Codd V, Mangino M, van der Harst P, et al Common variants near TERC are associated with mean telomere length. Nat Genet. 2010; 42: 197-9.
94. Mirabello L, Yu K, Kraft P, et al The association of telomere length and genetic variation in telomere biology genes. Human Mutat. 2010; 31: 1050-8.
95. Varadi V, Brendle A, Grzybowska E, et al A functional promoter polymorphism in the TERT gene does not affect inherited susceptibility to breast cancer. Cancer Genet Cytogenet. 2009; 190: 71-4.
96. Varadi V, Brendle A, Brandt A, et al Polymorphisms in telomere-associated genes, breast cancer susceptibility and prognosis. Eur J Cancer. 2009; 45: 3008-16.
97. Pooley KA, Tyrer J, Shah M, et al No association between TERT-CLPTM1L single nucleotide polymorphism rs401681 and mean telomere length or cancer risk. Cancer Epidemiol Biomarkers Prev. 2010; 19: 1862-5.
98. Liu Z, Li G, Wei S, et al Genetic variations in TERT-CLPTM1L genes and risk of squamous cell carcinoma of the head and neck. Carcinogenesis. 2010; 31: 1977-81.
99. Petersen GM, Amundadottir L, Fuchs CS, et al A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet. 2010; 42: 224-8.
100. Hsiung CA, Lan Q, Hong YC, et al The 5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia. PLoS Genet. 2010; 6: 1-9.
101. Jin G, Xu L, Shu Y, et al Common genetic variants on 5p15.33 contribute to risk of lung adenocarcinoma in a Chinese population. Carcinogenesis. 2009; 30: 987-90.
102. Kohno T, Kunitoh H, Shimada Y, et al Individuals susceptible to lung adenocarcinoma defined by combined HLA-DQA1 and TERT genotypes. Carcinogenesis. 2010; 31: 834-41.
103. Wang Y, Broderick P, Matakidou A, et al Role of 5p15.33 (TERT-CLPTM1L), 6p21.33 and 15q25.1 (CHRNA5-CHRNA3) variation and lung cancer risk in never-smokers. Carcinogenesis. 2010; 31: 234-8.
104. Zienolddiny S, Skaug V, Landvik NE, et al The TERT-CLPTM1L lung cancer susceptibility variant associates with higher DNA adduct formation in the lung. Carcinogenesis. 2009; 30: 1368-71.
105. Yoon SL, Jung SI, Do EJ, et al Short rare hTERT-VNTR2-2nd alleles are associated with prostate cancer susceptibility and influence gene expression. BMC Cancer. 2010; 10: 1-10.
106. Rafnar T, Sulem P, Stacey SN, et al Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet. 2009; 41: 221-7.
107. Andrew AS, Gui J, Sanderson AC, et al Bladder cancer SNP panel predicts susceptibility and survival. Hum Genet. 2009; 125: 527-39.
108. Johnatty SE, Beesley J, Chen X, et al Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot". PLoS Genet. 2010; 6: 1-10.